股东方面，截至2025年3月31日，佰仁医疗股东户数3099户，较上次增加288户，户均持股市值35.28万 元，户均持股数量2.76万股。 北京佰仁医疗科技股份有限公司的主营业务是医疗器械的研发、生产、销售及服务。公司的主要产品是 心外科生物补片、胸外科生物补片、神经外科生物补片、人工生物心脏瓣膜、经导管主动脉瓣系统、瓣 膜成形环、肺动脉带瓣管道、涤纶补片及其他外科植入医疗器械产品等。 8月15日，佰仁医疗今日收盘122.3元，上涨2.57%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到98.80倍，总市值168.47亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，佰仁医疗排 名第104位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13佰仁医疗98.80115.1313.09168.47亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9 ...

Core Insights - The report highlights that the recent improvement in supply-demand policies is expected to partially reverse the current unfavorable economic situation, driven by increased domestic demand from projects like the Yaxia Hydropower Station and ongoing "anti-involution" policies [4][10] - The cyclical stocks have shown strong performance recently, with the market's expectations for price improvements rapidly increasing, indicating a potential continuation of market valuation support in the short term [4][10] - The report emphasizes that the current market environment is characterized by ample liquidity, which, combined with the low valuation levels of cyclical sectors, has contributed to the rapid upward movement of these stocks [4][10] Stock Recommendations - The August stock selection includes: SF Express (transportation), Satellite Chemical (chemicals), Anji Technology (chemicals), Heng Rui Medicine (pharmaceuticals), Bairen Medical (pharmaceuticals), Beijing Renli (services), Feiliwa (electronics), Industrial Fulian (electronics), Pengding Holdings (electronics), and Hehe Information (computers) [10][11] - The report notes that the July stock selection achieved an absolute return of 9.64%, outperforming the market benchmark (CSI 300) by 6.10 percentage points, with individual stocks like Jitu Express-W and Shenghong Technology yielding returns of 57.23% and 42.94%, respectively [6][10] Industry Analysis Transportation Sector - SF Express reported a steady growth in Q1 2025, with a net profit of 2.234 billion yuan, a year-on-year increase of 16.87%, driven by an improved product matrix and service competitiveness [12][13] Chemical Sector - Satellite Chemical achieved a record high net profit in Q4 2024, benefiting from stable raw material prices and increased sales margins, with a sales gross margin of 27.11% [14][15] - Anji Technology experienced rapid revenue growth in 2024, with a gross margin of 58.45%, attributed to market expansion and product diversification [17][18] Pharmaceutical Sector - Heng Rui Medicine's overseas licensing agreements have contributed to significant revenue growth, with Q4 2024 net profit increasing by 107.20% year-on-year [20][21] - Bairen Medical's revenue growth was driven by the successful launch of its first interventional valve product, which significantly boosted its performance in 2024 [22][23] Service Sector - Beijing Renli has a strong market presence in the human resources industry, with a broad service offering and a robust client base, positioning it for continued growth [25][26] Electronics Sector - Feiliwa is expanding its production capacity in quartz fiber cloth, targeting the growing demand in the PCB market, with a projected CAGR of 12% from 2024 to 2029 [27][28] - Industrial Fulian's cloud computing business has shown significant growth, with revenue from AI servers increasing by over 150% [31][32] - Pengding Holdings is expected to achieve steady revenue and profit growth in the first half of 2025, driven by cost control and product structure optimization [33][34]

Core Viewpoints - The market in June is expected to remain in a consolidation phase, with large-cap stocks likely to see a recovery. Domestic demand momentum is anticipated to improve marginally, while April's industrial profits continued to show a recovery trend but experienced a decline in both volume and price. The cost decline was the main driver of profit growth in April. PMI data for May indicates a slight recovery in domestic production demand compared to April. It is expected that growth-stabilizing policies will be implemented alongside resilient external demand, and the trend of weak inventory replenishment is likely to continue in the second quarter. However, global trade policies remain uncertain, compounded by concerns over rising US debt rates, which may pressure market sentiment in the short term. In June, various growth-stabilizing policies are expected to accelerate, maintaining a cautious and oscillating market environment. Key areas to watch for a breakthrough include developments in overseas tariffs and the implementation of domestic growth-stabilizing policies in June [4][10][12]. June Stock Recommendations - The June stock selection by the report includes: - SF Express (Transportation) - Anji Technology (Chemicals) - Bairen Medical (Pharmaceuticals) - Lingnan Holdings (Social Services) - Qingdao Beer (Food and Beverage) - Suochen Technology (Computers) [10][12]. Industry Summaries Transportation Industry: SF Express - SF Express reported a net profit of 2.234 billion yuan in Q1 2025, reflecting a steady growth trend. The company achieved a total express volume of 3.56 billion parcels, a year-on-year increase of 19.7%, with revenue reaching 69.85 billion yuan, up 6.9% year-on-year. The profit growth was primarily driven by the continuous improvement of the product matrix and enhanced service competitiveness. The company also focused on cost control through operational model reforms and network optimization, achieving a gross profit margin of 13.3%, an increase of 0.1 percentage points year-on-year [12][13]. Chemical Industry: Anji Technology - Anji Technology experienced rapid growth in revenue and net profit in 2024 and Q1 2025, driven by increased market coverage and new product introductions. The gross profit margin for 2024 was 58.45%, with a net profit margin of 29.08%. In Q1 2025, the gross profit margin was 55.70%, and the net profit margin was 30.96%. The company is seeing a steady increase in its global market share for polishing liquids, with a projected market size growth for semiconductor CMP polishing materials [14][15]. Pharmaceutical Industry: Bairen Medical - Bairen Medical reported rapid growth in revenue and profit in 2024, with significant increases in its three main business segments. The heart valve replacement and repair segment saw a year-on-year growth of 64.28%. The company is expected to maintain high growth rates in 2025, driven by the approval of its first interventional valve product, which offers significant advantages in terms of operation and safety [17][18]. Social Services Industry: Lingnan Holdings - Lingnan Holdings achieved a revenue of 4.309 billion yuan in 2024, a year-on-year increase of 25.43%, and a net profit of 150 million yuan, up 116.08%. The company’s travel agency operations and hotel management segments are expected to continue growing, particularly with the recovery of inbound tourism and the expansion of hotel management projects [20][21]. Food and Beverage Industry: Qingdao Beer - Qingdao Beer faced pressure on volume and price in Q3 2024, with a year-on-year decline in sales volume of 7.0%. However, the company benefited from a decrease in raw material costs, leading to an improvement in gross profit margins. Future growth is anticipated as restaurant demand recovers, supported by the company's strong brand and distribution network [23][24]. Computer Industry: Suochen Technology - Suochen Technology reported a revenue of 39 million yuan in Q1 2025, a year-on-year increase of 21.73%. The company is focusing on enhancing its CAE software capabilities and exploring AI applications in various fields. The engineering simulation software segment has shown significant growth, contributing to an overall increase in the company's gross profit margin [25][26][27].

Strategy Overview - The market in June is expected to remain in a state of waiting for a breakthrough, with large-cap stocks likely to see a recovery. Domestic demand momentum is anticipated to improve marginally, although April's industrial profits showed a decline in both volume and price, with cost reductions being the main driver for profit growth. The PMI for May indicates a slight recovery in domestic production demand compared to April. It is expected that growth-stabilizing policies will be implemented alongside resilient external demand, continuing the trend of weak inventory replenishment in the second quarter. However, global trade policies remain uncertain, compounded by concerns over rising US debt rates, which may pressure market sentiment in the short term. In June, various growth-stabilizing policies are expected to accelerate, maintaining a volatile consolidation pattern in the market. Key areas to monitor for a breakthrough include overseas tariff developments and the implementation of domestic growth-stabilizing policies in June. [5][7] June Stock Recommendations - The June stock selection by Zhongyin Securities includes: - SF Express (Transportation) - Anji Technology (Chemicals) - Bairen Medical (Healthcare) - Lingnan Holdings (Social Services) - Qingdao Beer (Food and Beverage) - Suochen Technology (Computers) [14][16] Performance Review of May Stock Selection - The stock selection for May outperformed the market, with notable performances from Jiemian Express-W and Yiwei Lithium Energy, both achieving over 10% monthly returns. The absolute return of the May stock selection was 3.87%, outperforming the market benchmark (CSI 300) by 2.02 percentage points. Three stocks achieved excess returns of over 5% compared to the CSI 300. [9] Company-Specific Insights SF Express (Transportation) - In Q1 2025, SF Express reported a net profit of 2.234 billion yuan, reflecting a stable growth trend. The company achieved a total express volume of 3.56 billion parcels, a year-on-year increase of 19.7%, with revenue reaching 69.85 billion yuan, up 6.9% year-on-year. The net profit increased by 16.87% year-on-year, driven by continuous improvement in product matrix and service competitiveness. The gross profit margin was 13.3%, slightly up by 0.1 percentage points. [16][17] Anji Technology (Chemicals) - Anji Technology is expected to see rapid growth in revenue and net profit in 2024, driven by increased market coverage and new product introductions. The gross margin for 2024 is projected at 58.45%, up 2.64 percentage points year-on-year. The company’s polishing liquid revenue reached 1.545 billion yuan in 2024, a year-on-year increase of 43.73%. The global semiconductor CMP polishing materials market is expected to grow from 3.42 billion USD in 2024 to 3.62 billion USD in 2025. [19][20] Bairen Medical (Healthcare) - Bairen Medical reported rapid growth in Q4 2024 and Q1 2025, with significant increases in revenue across all three major business segments. The heart valve replacement and repair segment saw a year-on-year growth of 64.28%. The approval of the TAVR product in August 2024 is expected to drive further growth in 2025. [24][25] Lingnan Holdings (Social Services) - Lingnan Holdings achieved a revenue of 4.309 billion yuan in 2024, a year-on-year increase of 25.43%, with a net profit of 150 million yuan, up 116.08%. The travel agency and hotel management segments are expected to continue growing, particularly with the recovery of inbound tourism. [29][30] Qingdao Beer (Food and Beverage) - Qingdao Beer faced challenges in 2024 with a volume decline of 7.0% and a slight price increase of 0.5%. The company’s gross margin improved due to lower raw material costs, but net profit margin slightly decreased. Future growth is anticipated as restaurant demand recovers. [34][35] Suochen Technology (Computers) - Suochen Technology reported a revenue of 39 million yuan in Q1 2025, a year-on-year increase of 21.73%. The company is focusing on enhancing its CAE software capabilities and exploring AI applications in various fields. [38][39][40]

Core Viewpoint - The company reported strong revenue and profit growth in 2024 and Q1 2025, driven by new product launches and a stable cost structure, indicating a positive outlook for future performance [1][2][3]. Revenue Performance - In 2024, the company achieved revenue of 502 million yuan, a year-on-year increase of 35.41%, with all three major business segments showing growth: heart valve replacement and repair up 64.28%, congenital heart disease intervention up 15.24%, and soft tissue repair up 19.89% [1]. - In Q1 2025, revenue reached 100 million yuan, a year-on-year increase of 31.30%, with net profit soaring by 290.69% to 33 million yuan [1]. Cost and Margin Analysis - The gross margin for medical device products was 88.48% in 2024, with specific segments showing varying margins: heart valve replacement at 91.65%, congenital heart disease intervention at 88.73%, and soft tissue repair at 82.89% [2]. - The company maintained stable operating costs, with a slight increase in R&D expenses, reflecting a commitment to product development [2]. Profitability Insights - Despite high R&D investments of 151 million yuan in 2024 (up 53.26%), the company still achieved a net profit of 146 million yuan, a year-on-year increase of 27.02% [3]. - In Q1 2025, R&D expenses decreased, suggesting potential for further profit growth as the high investment phase concludes [3]. Product Innovation and Market Expansion - The heart valve replacement segment saw significant advancements, including patent approvals and ongoing clinical trials for new products, contributing to a 24.59% increase in sales volume [4]. - The company is expanding its product applications, including three collagen fillers, which are expected to gradually contribute to revenue [5]. Future Outlook - The company anticipates continued revenue growth, projecting revenues of 698 million yuan, 973 million yuan, and 1.288 billion yuan for 2025-2027, with net profits of 245 million yuan, 389 million yuan, and 531 million yuan respectively [6]. - The expansion of TAVR indications and increasing heart surgery demand are expected to drive market growth [6].